Princeton University Library Catalog

Targeting protein kinases for cancer therapy / David J. Matthews, Mary E. Gerritsen.

Author:
Matthews, David J. (David John), 1965- [Browse]
Format:
Book
Language:
English
Published/​Created:
Hoboken, N.J. : John Wiley & Sons, c2010.
Description:
xiii, 702 p. : ill. (chiefly col.) ; 25 cm.
Summary note:
"Research has shown that protein kinases can instigate the formation and spread of cancer when they transmit faulty signals inside cells. Because of this fact, pharmaceutical scientists have targeted kinases for intensive study, and have been working to develop medicinal roadblocks to sever their malignant means of communication." "Complete with full-color presentations, Targeting Protein Kinases for Cancer Therapy defines the structural features of protein kinases and examines their cellular functions. Combining kinase biology with chemistry and pharmacology applications, this book enlists emerging data to drive the discovery of new cancer-fighting drugs."--BOOK JACKET.
Bibliographic references:
Includes bibliographical references and index.
Contents:
1. Kinases and Cancer -- 1.1. A Brief History of Protein Phosphorylation -- 1.2. Kinases and Cancer -- 1.3. A Tour of the Human Protein Kinase Superfamily -- 1.4. Strategic Considerations for Selecting Kinases as Drug Targets -- 1.5. Comparison of Kinase Inhibitor Therapeutic Strategies -- 2. Protein Kinase Structure, Function, and Regulation -- 2.1. Ligand Binding to Receptor Tyrosine Kinases -- 2.2. Protein Kinase Domain Structure and Function -- 2.3. Catalytic Activity of Protein Kinases -- 2.4. Protein Kinase Regulation -- 3. Receptor Tyrosine Kinases -- 3.1. EGF/ERBB Receptors -- 3.2. Insulin/IGF Receptors -- 3.3. Anaplastic Lymphoma Kinase -- 3.4. VEGF Receptors (VEGFR1, VEGFR2, VEGFR3) -- 3.5. PDGF Receptors -- 3.6. FGF Receptors -- 3.7. KIT -- 3.8. FLT3 -- 3.9. RET -- 3.10. MET and RON -- 4. Nonreceptor Tyrosine Kinases -- 4.1. ABL -- 4.2. ARG -- 4.3. SRC and SRC Family Kinases -- 4.4. FAK -- 4.5. JAK2 -- 5. Intracellular Signal Transduction Cascades -- 5.1. The PI3K/PTEN Pathway -- 5.2. mTOR Signaling -- 5.3. MAPK Signaling Pathways -- 5.4. PIM Kinases -- 5.5. Protein Kinase C -- 6. Cell Cycle Control -- 6.1. Cyclin-Dependent Kinases (CDKs) and Cell Cycle Progression -- 6.2. CDKs and mRNA Production -- 6.3. Other CDK-Related Kinases -- 6.4. Mitotic Kinases -- 6.5. Cell Cycle Checkpoint Kinases -- 7. Structural Biochemistry of Kinase Inhibitors -- 7.1. Strategies for Inhibitor Design -- 7.2. Architecture of the ATP Binding Site: DFG-in -- 7.3. Case Study: Inhibitors of CHK1 -- 7.4. Case Study: Inhibitors of CDK2 -- 7.5. Case Study: Inhibitors of SRC Family Kinases -- 7.6. Case Study: EGF Receptor Inhibitors -- 7.7. Targeting the Inactive Conformation -- 7.8. Noncompetitive Inhibition -- 7.9. Kinase Inhibitor Specificity -- 8. Tyrosine Kinase Inhibitors -- 8.1. BCR-ABL Inhibitors -- 8.2. SRC Inhibitors -- 8.3. JAK2 Inhibitors -- 8.4. EGFR/ERBB Inhibitors -- 8.5. IGFIR Inhibitors -- 8.6. FLT3 Inhibitors -- 8.7. KIT Inhibitors -- 8.8. MET/RON Inhibitors -- 8.9. RET Inhibitors -- 8.10. Other Inhibitors -- 9. Angiokinase Inhibitors -- 9.1. Introduction -- 9.2. Angiokinase Inhibitors -- 10. Intra Cellular Signaling Kinase Inhibitors -- 10.1. mTOR Inhibitors -- 10.2. PI3K Inhibitors -- 10.3. RAF Kinase Inhibitors -- 10.4. MEK Inhibitors -- 10.5. CDK Inhibitors -- 10.6. Cell Cycle Checkpoint Kinase Inhibitors -- 10.7. Mitotic Kinase Inhibitors -- 11. Current Challenges and Future Directions -- 11.1. Kinase Inhibitor Drug Resistance -- 11.2. Combination Therapy With Kinase Inhibitors -- 11.3. Systems Biology and Translational Medicine -- 11.4. Conclusions.
Subject(s):
ISBN:
  • 9780470229651 (cloth)
  • 0470229659 (cloth)
LCCN:
2009020804
OCLC:
338289165
Related name:
RCP:
C - S